Literature DB >> 28821684

Medication overuse headache: An entrenched idea in need of scrutiny.

Ann I Scher1, Paul B Rizzoli2, Elizabeth W Loder2.   

Abstract

It is a widely accepted idea that medications taken to relieve acute headache pain can paradoxically worsen headache if used too often. This type of secondary headache is referred to as medication overuse headache (MOH); previously used terms include rebound headache and drug-induced headache. In the absence of consensus about the duration of use, amount, and type of medication needed to cause MOH, the default position is conservative. A common recommendation is to limit treatment to no more than 10 or 15 days per month (depending on medication type) to prevent headache frequency progression. Medication withdrawal is often recommended as a first step in treatment of patients with very frequent headaches. Existing evidence, however, does not provide a strong basis for such causal claims about the relationship between medication use and frequent headache. Observational studies linking treatment patterns with headache frequency are by their nature confounded by indication. Medication withdrawal studies have mostly been uncontrolled and often have high dropout rates. Evaluation of this evidence suggests that only a minority of patients required to limit the use of symptomatic medication may benefit from treatment limitation. Similarly, only a minority of patients deemed to be overusing medications may benefit from withdrawal. These findings raise serious questions about the value of withholding or withdrawing symptom-relieving medications from people with frequent headaches solely to prevent or treat MOH. The benefits of doing so are smaller, and the harms larger, than currently recognized. The concept of MOH should be viewed with more skepticism. Until the evidence is better, we should avoid dogmatism about the use of symptomatic medication. Frequent use of symptom-relieving headache medications should be viewed more neutrally, as an indicator of poorly controlled headaches, and not invariably a cause.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 28821684     DOI: 10.1212/WNL.0000000000004371

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  What the pharmacological management of migraine can tell us about the future of migraine patient care.

Authors:  Paul B Rizzoli
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

2.  Prevalence and comorbidity of migraine headache: results from the Singapore Mental Health Study 2016.

Authors:  Anitha Jeyagurunathan; Edimansyah Abdin; Janhavi Ajit Vaingankar; Boon Yiang Chua; Saleha Shafie; Shi Hui Sherilyn Chang; Lyn James; Kelvin Bryan Tan; Sutapa Basu; Siow Ann Chong; Mythily Subramaniam
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-08-27       Impact factor: 4.328

Review 3.  Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents.

Authors:  Hans-Christoph Diener; Dagny Holle; Thomas Dresler; Charly Gaul
Journal:  Dtsch Arztebl Int       Date:  2018-06-01       Impact factor: 5.594

4.  Quality Improvement in Neurology: Headache Quality Measurement Set.

Authors:  Matthew S Robbins; M Cristina C Victorio; Mark Bailey; Calli Cook; Ivan Garza; J Stephen Huff; Duren Ready; Nathaniel M Schuster; David Seidenwurm; Elizabeth Seng; Christina Szperka; Erin Lee; Raissa Villanueva
Journal:  Headache       Date:  2020-09-23       Impact factor: 5.887

5.  Quality improvement in neurology: Headache Quality Measurement Set.

Authors:  Matthew S Robbins; M Cristina Victorio; Mark Bailey; Calli Cook; Ivan Garza; J Stephen Huff; Duren Ready; M Schuster Nathaniel; David Seidenwurm; Elizabeth Seng; Christina Szperka; Erin Lee; Raissa Villanueva
Journal:  Neurology       Date:  2020-09-23       Impact factor: 9.910

Review 6.  The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update.

Authors:  Christina Sun-Edelstein; Alan M Rapoport; Wanakorn Rattanawong; Anan Srikiatkhachorn
Journal:  CNS Drugs       Date:  2021-05-17       Impact factor: 5.749

7.  Alteration of gray matter texture features over the whole brain in medication-overuse headache using a 3-dimentional texture analysis.

Authors:  Zhiye Chen; Xiaoyan Chen; Zhiqiang Chen; Mengqi Liu; Huiguang He; Lin Ma; Shengyuan Yu
Journal:  J Headache Pain       Date:  2017-11-28       Impact factor: 7.277

8.  Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology.

Authors:  Alessandro Viganò; Maria Claudia Torrieri; Massimiliano Toscano; Francesca Puledda; Barbara Petolicchio; Tullia Sasso D'Elia; Angela Verzina; Sonia Ruggiero; Marta Altieri; Edoardo Vicenzini; Jean Schoenen; Vittorio Di Piero
Journal:  J Headache Pain       Date:  2018-08-20       Impact factor: 7.277

9.  Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.

Authors:  Chun-Shuo Shan; Qing-Qing Xu; Yi-Hua Shi; Yong Wang; Zhang-Xin He; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2018-06-27       Impact factor: 5.810

Review 10.  Medication-overuse headache: a widely recognized entity amidst ongoing debate.

Authors:  Nicolas Vandenbussche; Domenico Laterza; Marco Lisicki; Joseph Lloyd; Chiara Lupi; Hannes Tischler; Kati Toom; Fenne Vandervorst; Simone Quintana; Koen Paemeleire; Zaza Katsarava
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.